{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:21:43Z","timestamp":1781796103443,"version":"3.54.5"},"reference-count":31,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.bcmd.2013.09.002","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T23:30:06Z","timestamp":1389223806000},"page":"121-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy"],"prefix":"10.1016","volume":"52","author":[{"given":"Cristian","family":"Ferri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Bianchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Bengi\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Larripa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2013.09.002_bb0005","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.bcmd.2013.09.002_bb0010","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcmd.2013.09.002_bb0015","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","article-title":"Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?","volume":"114","author":"Branford","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2013.09.002_bb0020","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/sj.leu.2404137","article-title":"The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib","volume":"20","author":"Khorashad","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2013.09.002_bb0025","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.hoc.2011.09.005","article-title":"BCR-ABL mutations in chronic myeloid leukemia","volume":"25","author":"Ernst","year":"2011","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.bcmd.2013.09.002_bb0030","first-page":"93","article-title":"Detection of BCR-ABL mutations and resistance to imatinib mesylate","volume":"125","author":"Branford","year":"2006","journal-title":"Methods Mol. Med."},{"key":"10.1016\/j.bcmd.2013.09.002_bb0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/leu.2010.238","article-title":"Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia","volume":"25","author":"Bixby","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2013.09.002_bb0040","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2013.09.002_bb0045","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/BF02981952","article-title":"Mechanisms of transformation by the BCR\/ABL oncogene","volume":"73","author":"Sattler","year":"2001","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.bcmd.2013.09.002_bb0050","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1084\/jem.189.8.1229","article-title":"Signal transducer and activator of transcription (STAT) 5 activation by BCR\/ABL is dependent on intact Src homology (SH) 3 andSH2 domains of BCR\/ABL and is required for leukemogenesis","volume":"189","author":"Nieborowska-Skorska","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcmd.2013.09.002_bb0055","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/sj.leu.2401429","article-title":"Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth","volume":"13","author":"Roginskaya","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2013.09.002_bb0060","first-page":"3589","article-title":"Activation of Src kinases p53\/56lyn and p59hck by p210bcr\/abl in myeloid cells","volume":"56","author":"Danhauser-Riedl","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcmd.2013.09.002_bb0065","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2013.09.002_bb0070","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1756-8722-3-47","article-title":"First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib","volume":"3","author":"Wei","year":"2010","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bcmd.2013.09.002_bb0080","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/ng1343","article-title":"Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia","volume":"36","author":"Hu","year":"2004","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcmd.2013.09.002_bb0085","doi-asserted-by":"crossref","first-page":"18581","DOI":"10.1074\/jbc.C000126200","article-title":"Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck","volume":"275","author":"Lionberger","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcmd.2013.09.002_bb0090","doi-asserted-by":"crossref","first-page":"8075","DOI":"10.1038\/sj.onc.1206008","article-title":"Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis","volume":"21","author":"Wilson","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.bcmd.2013.09.002_bb0095","doi-asserted-by":"crossref","first-page":"30907","DOI":"10.1074\/jbc.M605902200","article-title":"Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity","volume":"281","author":"Meyn","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcmd.2013.09.002_bb0100","doi-asserted-by":"crossref","first-page":"33260","DOI":"10.1074\/jbc.272.52.33260","article-title":"The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr","volume":"272","author":"Warmuth","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcmd.2013.09.002_bb0105","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2009-06-228130","article-title":"PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice","volume":"115","author":"Peng","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2013.09.002_bb0110","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nature05933","article-title":"A transforming mutation in the pleckstrin homology domain of AKT1 in cancer","volume":"448","author":"Carpten","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2013.09.002_bb0115","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1126\/science.275.5308.1943","article-title":"PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer","volume":"275","author":"Li","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.bcmd.2013.09.002_bb0120","doi-asserted-by":"crossref","first-page":"13375","DOI":"10.1074\/jbc.273.22.13375","article-title":"The tumor suppressor, PTEN\/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate","volume":"273","author":"Maehama","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcmd.2013.09.002_bb0125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0092-8674(00)81780-8","article-title":"Negative regulation of PKB\/Akt-dependent cell survival by the tumor suppressor PTEN","volume":"95","author":"Stambolic","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.bcmd.2013.09.002_bb0130","doi-asserted-by":"crossref","first-page":"8347","DOI":"10.1074\/jbc.274.13.8347","article-title":"The role of phosphoinositide 3-kinase lipid products in cell function","volume":"274","author":"Rameh","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcmd.2013.09.002_bb0135","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.1242\/jcs.02606","article-title":"Selective cellular effects of overexpressed pleckstrin-homology domains that recognize PtdIns(3,4,5)P3 suggest their interaction with protein binding partners","volume":"118","author":"Va'rnai","year":"2005","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bcmd.2013.09.002_bb0140","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3109\/10428194.2012.718767","article-title":"Early detection and quantification of mutations in the tyrosine kinase domain of chimerical BCR-ABL1 gene combining high-resolution melting analysis and mutant-allele specific quantitative polymerase chain reaction","volume":"54","author":"Ferri","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bcmd.2013.09.002_bb0145","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2013.09.002_bb0155","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2013.09.002_bb0160","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djn188","article-title":"Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase","volume":"100","author":"Wu","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bcmd.2013.09.002_bb0165","doi-asserted-by":"crossref","first-page":"156","DOI":"10.18632\/oncotarget.119","article-title":"Role of Pten in leukemia stem cells","volume":"1","author":"Peng","year":"2010","journal-title":"Oncotarget"}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979613002064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979613002064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:29:32Z","timestamp":1761049772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979613002064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":31,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S1079979613002064"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2013.09.002","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2013.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}